We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Investigating plasma levels as a biomarker for Alzheimer's disease
News

Investigating plasma levels as a biomarker for Alzheimer's disease

Investigating plasma levels as a biomarker for Alzheimer's disease
News

Investigating plasma levels as a biomarker for Alzheimer's disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Investigating plasma levels as a biomarker for Alzheimer's disease "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The first detailed study of relationship between plasma Aβ levels, cognitive function and the measures studying the size of brain, which shrinks with Alzheimer's disease -


A Centre for Healthy Brain Ageing (CHeBA) paper published in Current Alzheimer Research presents the first detailed study of the relationship between plasma levels of two amyloid beta peptides (Aβ1-40 and Aβ1-42), brain volumetrics (measures studying the size of brain, which shrinks with Alzheimer's disease) and cognitive performance in an investigation of the usefulness of plasma levels as a biomarker for Alzheimer's disease (AD).


See Also: Amyloid plaques may be strangling blood flow


Lead author on the paper and head of CHeBA's Proteomics Group at the University of New South Wales, Dr Anne Poljak, said that since amyloid beta (Aβ) peptides are the main component of the amyloid plaques found in Alzheimer patients' brains, changes in levels of Aβ in blood plasma may provide a biomarker for detecting increased risk or early diagnosis of disease.


"While Aβ has traditionally been measured using cerebrospinal fluid, plasma presents a more accessible sample for routine collection and screening although results to date have been variable," Dr Poljak said.


The study examined age-matched cognitively normal controls (n=126), individuals with amnestic mild cognitive impairment (aMCI, n=89) from CHeBA's Sydney Memory & Ageing Study, as well as individuals with Alzheimer's disease (AD, n=39).


Learn More: Is the amyloid hypothesis the right path to find a treatment for Alzheimer's disease?


Plasma levels of the two peptides and the Aβ1-42/1-40 ratio were lower in aMCI and Alzheimer's disease than in cognitively normal controls, and lower levels of Aβ1-42 were associated with lower global cognition and hippocampal volume and higher levels of white matter hyperintensities (which are believed to contribute to Alzheimer's disease). A genetic component was also identified, with associations between Aβ1-40 and cognitive and brain volume measures predominantly observed in individuals carrying the ε4 allele, while the opposite was observed in non-carriers. Longitudinal analysis revealed greater decline in global cognition and memory for the highest quintiles of Aβ1-42 and the ratio measure.


Director of CHeBA and co-author on the paper, Professor Perminder Sachdev, said he was encouraged by the findings.


"These findings certainly suggest that plasma Aβ measures may serve as biomarkers of Alzheimer's disease," he said.


Note: Material may have been edited for length and content. For further information, please contact the cited source.

University of New South Wales   press release


Publication

Poljak A et al. The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study.   Current Alzheimer Research, Published 2016. doi: 10.2174/1567205013666151218150202


Advertisement